All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Does upfront treatment with venetoclax, lenalidomide, and rituximab enhance tumor responses in MCL?

During the 2021 ASCO Annual Meeting, the Lymphoma Hub spoke with Tycel Phillips, University of Michigan, Ann Arbor, US. We asked, Does upfront treatment with venetoclax, lenalidomide, and rituximab enhance tumor responses in mantle cell lymphoma (MCL)?

Does upfront treatment with venetoclax, lenalidomide, and rituximab enhance tumor responses in MCL?

To answer this question, Phillips describes a phase I trial investigating complete response rate and minimal residual disease (MRD) detectability when using this triplet regimen in untreated patients with MCL.

Share: